Women's Health Market Size, Share & Trends Analysis Report by Application (Postmenopausal Osteoporosis, Infertility, Endometriosis & Uterine Fibroids, Menopause, PCOS), Age, Region, and Segment Forecasts, 2024-2030

The global women’s health market size is expected to reach USD 67.07 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030. The introduction of innovative novel products and the presence of a strong pipeline of women’s health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women’s health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women’s Health Market Report Highlights

The contraceptives segment held the highest market share of more than 35.25% of the global revenue in 2023 due to increased awareness about family planning and rapid technological advancements in contraception
The University of California Bixby Center released a reimbursement guide to help health providers offer women a full range of contraceptives
The endometriosis segment is expected to witness significant growth over the forecast period due to the launch of products, such as Relugoliz and the impending launch of Linzagolix for the treatment of women with uterine fibroids
Based on age, the 50 years and above segment is expected to register the fastest growth rate of 6.7% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe
According to the International Menopause Society, globally, women aged between 45 and 55 years typically experience menopause, with the average age of onset at 51.5 years

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Age
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. Age outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Women’s Health Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of target diseases
3.2.1.2. Increasing initiatives by government and various organizations
3.2.1.3. Rising publicly funded family planning services
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of major drugs
3.2.2.2. Lawsuits related to products
3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices
3.3. Women’s Health Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic Landscape

Chapter 4. Women’s Health Market: Application Estimates & Trend Analysis

4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Women’s Health Market by Application Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Hormonal infertility
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Contraceptives
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Postmenopausal osteoporosis
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Endometriosis & uterine fibroids
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Menopause
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Polycystic ovary syndrome (PCOS)
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Women’s Health Market: Age Estimates & Trend Analysis

5.1. Treatment Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Women’s Health Market by Age Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. 50 years and above
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Postmenopausal osteoporosis
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Endometriosis & uterine fibroids
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.4. Menopause
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.5. Others
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Others
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Women’s Health Market: Regional Estimates & Trend Analysis

6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia-Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. AbbVie, Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Bayer AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Merck & Co., Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Pfizer, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Teva Pharmaceutical Industries Ltd.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Agile Therapeutics
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Amgen, Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Apothecus Pharmaceutical Corp.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Blairex Laboratories, Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Ferring B.V.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 North America women’s health market, by region, 2018-2030 (USD Million)
Table 3 North America women’s health market, by application, 2018-2030 (USD Million)
Table 4 North America women’s health market, by age, 2018-2030 (USD Million)
Table 5 U.S. women’s health market, by application, 2018-2030 (USD Million)
Table 6 U.S. women’s health market, by age, 2018-2030 (USD Million)
Table 7 Canada women’s health market, by application, 2018-2030 (USD Million)
Table 8 Canada women’s health market, by age, 2018-2030 (USD Million)
Table 9 Europe women’s health market, by region, 2018-2030 (USD Million)
Table 10 Europe women’s health market, by application, 2018-2030 (USD Million)
Table 11 Europe women’s health market, by age, 2018-2030 (USD Million)
Table 12 Germany women’s health market, by application, 2018-2030 (USD Million)
Table 13 Germany women’s health market, by age, 2018-2030 (USD Million)
Table 14 UK women’s health market, by application, 2018-2030 (USD Million)
Table 15 UK women’s health market, by age, 2018-2030 (USD Million)
Table 16 France women’s health market, by application, 2018-2030 (USD Million)
Table 17 France women’s health market, by age, 2018-2030 (USD Million)
Table 18 Italy women’s health market, by application, 2018-2030 (USD Million)
Table 19 Italy women’s health market, by age, 2018-2030 (USD Million)
Table 20 Spain women’s health market, by application, 2018-2030 (USD Million)
Table 21 Spain women’s health market, by age, 2018-2030 (USD Million)
Table 22 Denmark women’s health market, by application, 2018-2030 (USD Million)
Table 23 Denmark women’s health market, by age, 2018-2030 (USD Million)
Table 24 Sweden women’s health market, by application, 2018-2030 (USD Million)
Table 25 Sweden women’s health market, by age, 2018-2030 (USD Million)
Table 26 Norway women’s health market, by application, 2018-2030 (USD Million)
Table 27 Norway women’s health market, by age, 2018-2030 (USD Million)
Table 28 Asia-Pacific women’s health market, by region, 2018-2030 (USD Million)
Table 29 Asia-Pacific women’s health market, by application, 2018-2030 (USD Million)
Table 30 Asia-Pacific women’s health market, by age, 2018-2030 (USD Million)
Table 31 China women’s health market, by application, 2018-2030 (USD Million)
Table 32 China women’s health market, by age, 2018-2030 (USD Million)
Table 33 Japan women’s health market, by application, 2018-2030 (USD Million)
Table 34 Japan women’s health market, by age, 2018-2030 (USD Million)
Table 35 India women’s health market, by application, 2018-2030 (USD Million)
Table 36 India women’s health market, by age, 2018-2030 (USD Million)
Table 37 South Korea women’s health market, by application, 2018-2030 (USD Million)
Table 38 South Korea women’s health market, by age, 2018-2030 (USD Million)
Table 39 Australia women’s health market, by application, 2018-2030 (USD Million)
Table 40 Australia women’s health market, by age, 2018-2030 (USD Million)
Table 41 Thailand women’s health market, by application, 2018-2030 (USD Million)
Table 42 Thailand women’s health market, by age, 2018-2030 (USD Million)
Table 43 Latin America women’s health market, by region, 2018-2030 (USD Million)
Table 44 Latin America women’s health market, by age, 2018-2030 (USD Million)
Table 45 Latin America women’s health market, by application, 2018-2030 (USD Million)
Table 46 Brazil women’s health market, by application, 2018-2030 (USD Million)
Table 47 Brazil women’s health market, by age, 2018-2030 (USD Million)
Table 48 Mexico women’s health market, by application, 2018-2030 (USD Million)
Table 49 Mexico women’s health market, by age, 2018-2030 (USD Million)
Table 50 Argentina women’s health market, by application, 2018-2030 (USD Million)
Table 51 Argentina women’s health market, by age, 2018-2030 (USD Million)
Table 52 MEA women’s health market, by region, 2018-2030 (USD Million)
Table 53 MEA women’s health market, by application, 2018-2030 (USD Million)
Table 54 MEA women’s health market, by age, 2018-2030 (USD Million)
Table 55 South Africa women’s health market, by application, 2018-2030 (USD Million)
Table 56 South Africa women’s health market, by age, 2018-2030 (USD Million)
Table 57 Saudi Arabia women’s health market, by application, 2018-2030 (USD Million)
Table 58 Saudi Arabia women’s health market, by age, 2018-2030 (USD Million)
Table 59 UAE women’s health market, by application, 2018-2030 (USD Million)
Table 60 UAE women’s health market, by age, 2018-2030 (USD Million)
Table 61 Kuwait women’s health market, by application, 2018-2030 (USD Million)
Table 62 Kuwait women’s health market, by age, 2018-2030 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary Interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Women’s health market: market outlook
Figure 14 Women’s Health Competitive Insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Women’s health market driver impact
Figure 20 Women’s health market restraint impact
Figure 21 Women’s Health Market Strategic Initiatives Analysis
Figure 22 Women’s health market: Application movement analysis
Figure 23 Women’s health market: Application outlook and key takeaways
Figure 24 Hormonal infertility market estimates and forecast, 2018-2030
Figure 25 Contraceptives estimates and forecast, 2018-2030
Figure 26 Postmenopausal osteoporosis market estimates and forecast, 2018-2030
Figure 27 Endometriosis & uterine fibroids estimates and forecast, 2018-2030
Figure 28 Menopause market estimates and forecast, 2018-2030
Figure 29 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018-2030
Figure 30 Women’s Health Market: Age Movement Analysis
Figure 31 Women’s health market: Age outlook and key takeaways
Figure 32 50 years and above market estimates and forecasts, 2018-2030
Figure 33 Postmenopausal osteoporosis market estimates and forecasts,2018-2030
Figure 34 Endometriosis & uterine fibroids market estimates and forecasts,2018-2030
Figure 35 Menopause market estimates and forecasts,2018-2030
Figure 36 Others market estimates and forecasts,2018-2030
Figure 37 Others market estimates and forecasts,2018-2030
Figure 38 Global women’s health market: Regional movement analysis
Figure 39 Global women’s health market: Regional outlook and key takeaways
Figure 40 Global women’s health market share and leading players
Figure 41 North America market share and leading players
Figure 42 Europe market share and leading players
Figure 43 Asia-Pacific market share and leading players
Figure 44 Latin America market share and leading players
Figure 45 Middle East & Africa market share and leading players
Figure 46 North America: SWOT
Figure 47 Europe SWOT
Figure 48 Asia-Pacific SWOT
Figure 49 Latin America SWOT
Figure 50 MEA SWOT
Figure 51 North America, by country
Figure 52 North America
Figure 53 North America market estimates and forecasts, 2018-2030
Figure 54 U.S.
Figure 55 U.S. market estimates and forecasts, 2018-2030
Figure 56 Canada
Figure 57 Canada market estimates and forecasts, 2018-2030
Figure 58 Europe
Figure 59 Europe market estimates and forecasts, 2018-2030
Figure 60 UK
Figure 61 UK market estimates and forecasts, 2018-2030
Figure 62 Germany
Figure 63 Germany market estimates and forecasts, 2018-2030
Figure 64 France
Figure 65 France market estimates and forecasts, 2018-2030
Figure 66 Italy
Figure 67 Italy market estimates and forecasts, 2018-2030
Figure 68 Spain
Figure 69 Spain market estimates and forecasts, 2018-2030
Figure 70 Denmark
Figure 71 Denmark market estimates and forecasts, 2018-2030
Figure 72 Sweden
Figure 73 Sweden market estimates and forecasts, 2018-2030
Figure 74 Norway
Figure 75 Norway market estimates and forecasts, 2018-2030
Figure 76 Asia-Pacific
Figure 77 Asia-Pacific market estimates and forecasts, 2018-2030
Figure 78 China
Figure 79 China market estimates and forecasts, 2018-2030
Figure 80 Japan
Figure 81 Japan market estimates and forecasts, 2018-2030
Figure 82 India
Figure 83 India market estimates and forecasts, 2018-2030
Figure 84 Thailand
Figure 85 Thailand market estimates and forecasts, 2018-2030
Figure 86 South Korea
Figure 87 South Korea market estimates and forecasts, 2018-2030
Figure 88 Australia
Figure 89 Australia market estimates and forecasts, 2018-2030
Figure 90 Latin America
Figure 91 Latin America market estimates and forecasts, 2018-2030
Figure 92 Brazil
Figure 93 Brazil market estimates and forecasts, 2018-2030
Figure 94 Mexico
Figure 95 Mexico market estimates and forecasts, 2018-2030
Figure 96 Argentina
Figure 97 Argentina market estimates and forecasts, 2018-2030
Figure 98 Middle East and Africa
Figure 99 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 100 South Africa
Figure 101 South Africa market estimates and forecasts, 2018-2030
Figure 102 Saudi Arabia
Figure 103 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 104 UAE
Figure 105 UAE market estimates and forecasts, 2018-2030
Figure 106 Kuwait
Figure 107 Kuwait market estimates and forecasts, 2018-2030
Figure 108 Market share of key market players- Women’s health market

Companies Mentioned

AbbVie, Inc.
Bayer AG
Merck & Co., Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Agile Therapeutics
Amgen, Inc.
Apothecus Pharmaceutical Corp.
Blairex Laboratories, Inc.
Ferring B.V.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	130
Published	December 2023
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 44.36 Billion
Forecasted Market Value ( USD ) by 2030	$ 67.07 Billion
Compound Annual Growth Rate	5.4%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5842EUR$5,950USD£4,875GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6824EUR$6,950USD£5,694GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8788EUR$8,950USD£7,332GBP

Women’s Health Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Women's Health Market Report by Age Group Type (50 Years and Above, and Others), Application (Contraceptives, Osteoporosis, Menopause, Infertility, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

Women's Health Market by Age, Distribution Channel, Application - Global Forecast 2025-2030

Women's Health App Market Size, Share & Trends Analysis Report By Type (Fitness & Nutrition, Pregnancy Tracking & Postpartum Care, Menopause), By Modality (Smartphone, Tablet), By Region, And Segment Forecasts, 2024 - 2030

Women Reproductive Health Market (2024 Edition): Analysis By Treatment Type (Menstrual Disorder, Uterine Fibroids/ Endometriosis, Infertility, Menopausal Disorder), By Route of Administration, By End User, By Region: Market Insights and Forecast (2020-2030)

Endometriosis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, End-User - Global Forecast 2025-2030